Post-2022 extensions (20232025) Post-2022 outputs have largely been post-hoc and extension analyses of SURPASS cohorts examining cardiovascular risk factors, NAFLD (non-alcoholic fatty liver disease) biomarkers, albuminuria, and body-composition trajectories, rather than new receptor-mechanism experiments [10]
Altered arachidonic acid metabolism via COX-1 and COX-2 contributes to the endothelial dysfunction of penile arteries from obese Zucker rats
Among participants who met criteria for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) at baseline, more than 80% in the 8mg and 12mg cohorts no longer met those criteria after treatment effectively resolving their fatty liver disease
Evaluate your budget relative to your goals
"You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur," the agency added